Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412873 | 0.95 | ALDH1A1 (0.42) | TSHRGPR119CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL12282193 | 0.93 | ALDH1A1 (0.45) | TSHRGPR119CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL12283406 | 0.93 | ALDH1A1 (0.45) | TSHRGPR119CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL390019 | 0.93 | ALDH1A1 (0.45) | TSHRGPR119CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL29530296 | 0.84 | CYP1A2 (0.37) | TSHRGPR119CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL20424119 | 0.84 | CYP1A2 (0.37) | TSHRGPR119CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL1713429 | 0.82 | PDE4B (0.36) | GPR119CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL12207096 | 0.82 | TPSAB1 (0.39) | CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL10053019 | 0.82 | CYP1A2 (0.48) | TSHRGPR119CYP1A2ALDH1A1HRH2 | |
| SCHEMBL12184259 | 0.82 | PIK3CD (0.48) | TSHRGPR119CYP1A2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119955091-A | Polymer, positive-type negative-type photosensitive resin composition, pattern forming method, cured film forming method, interlayer insulating film, surface protective film, and electronic component | 信越化学工业株式会社 | 2025-05-09 | — | — | CN | disclosed |
| CN-118210199-A | Photosensitive resin composition, cured film pattern, and method for producing same | 奇美实业股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-115113484-A | Positive photosensitive resin composition, positive photosensitive dry film, method for producing the same, and method for forming pattern | 信越化学工业株式会社 | 2022-09-27 | — | — | CN | disclosed |
| CN-107561863-B | Positive photosensitive resin composition and application thereof | 奇美实业股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114253069-A | Photosensitive resin composition, pattern forming method, cured film forming method, interlayer insulating film, and surface protective film | 信越化学工业株式会社 | 2022-03-29 | — | — | CN | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| CN-104950580-B | Photosensitive polysiloxane composition and application thereof | 奇美实业股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| US-10162260-B2 | Photosensitive resin composition, protective film, and liquid crystal display element | CHI MEI CORPORATION (TW) | 2018-12-25 | — | — | US | disclosed |
| US-20170168390-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PROTECTIVE FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-15 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | TSHR 1150/4885GPR119 7/4885CYP1A2 993/4885 |
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | TSHR 4797/4885GPR119 3949/4885CYP1A2 2161/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | TSHR 4832/4885GPR119 3539/4885CYP1A2 2655/4885 |
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | TSHR 4482/4885GPR119 3257/4885CYP1A2 4607/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | TSHR 2962/4885GPR119 3077/4885CYP1A2 635/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | TSHR 4548/4885GPR119 3286/4885CYP1A2 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.